Fig. 3
Intracellular uptake and targeting ability in vivo of HA-ML@ES NPs. (A) Fluorescence images of CD44 in HUVECs and RAW264.7 after different treatments. [Hcy] = 100 µM. (B) Western blot analysis of CD44 on HUVECs and RAW264.7 after different treatment with (C) quantitative data at right. [Hcy] = 100 µM. (D) Representative images of CLSM of HUVECs and RAW264.7 after 4 h of incubation with Dil-HA-ML NPs. [Hcy] = 100 µM. Scale bar = 50 μm. (E) Flow cytometry analysis of HUVECs and (F) RAW264.7 after 4 h of incubation with PBS or Dil-HA-ML NPs. [Hcy] = 100 µM. (G) Schematic diagram of the co-culture pattern of HUVECs with RAW264.7 cells. (H) Confocal microscopy images and (I) fluorescence intensity of Dil-L@ES NPs and Dil-HA-ML NPs in HUVECs and RAW264.7 cells in a trans-well system. [Hcy] = 100 µM. Scale bar = 100 μm. (J) Ex vivo fluorescence images of Ce6 fluorescence in aortas 12 h after Ce6, ML@ESCe6 and HA-ML@ESCe6 NPs injection into ApoE−/− atherosclerotic mice. (K) CLSM analysis of the co-location of Ce6, ML@ESCe6 NPs and HA-ML@ESCe6 NPs (red) and endothelial cells (green), or Ce6, ML@ESCe6 NPs and HA-ML@ESCe6 NPs (red) and macrophages (green) in atherosclerotic plaques (n = 3) Date are mean ± SD (n = 3) *P < 0.05, **P < 0.01, ***P < 0.001